ADMA NASDAQ
Credit Risk of going bust: lower than 57% of companies Debt: 7.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.10 (down 99.1%), ADMA Biologics, Inc. would be worth roughly what it owes.
Total debt $203.8M against a stock market value of $2.48B.
Distance to default 5.90 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $100.2M (short-term plus half of long-term), stock volatility 55.4%; Altman Z'' 7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Ramsey, NJ 07446
US
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kestenberg-Messina K | F-InKind | 3,177 | $8.37 | 2026-07-24 |
| Kohler Terry | A-Award | 85,130 | — | 2026-07-16 |
| Kohler Terry | A-Award | 136,363 | $8.81 | 2026-07-16 |
| Grossman Jerrold B | P-Purchase | 6,400 | $7.91 | 2026-05-27 |
| Grossman Jerrold B | P-Purchase | 12,500 | $8.01 | 2026-05-12 |